⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ABBV News
ABBVIE INC.
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026
prnewswire.com
ABBV
AbbVie and Galderma Control 80% of Aesthetic Medicine's AI Citations, New 5W Index Finds
prnewswire.com
ABBV
RXT
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
prnewswire.com
ABBV
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda
globenewswire.com
ABBV
ALNY
ASTL
AZN
BIIB
BMY
CSL
LLY
GILD
GSK
MRK
NVS
NVO
PFE
REGN
SNY
SUN
TEVA
UPST
VRTX
Ichnos Glenmark Innovation (IGI) Announces Appointment of Mariana Cota Stirner, M.D., Ph.D., as Chief Medical Officer
globenewswire.com
ABBV
BMY
NVS
AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
prnewswire.com
ABBV
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
prnewswire.com
ABBV
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
prnewswire.com
ABBV
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
globenewswire.com
APGE
ROKU
TBRG
OGN
ABBV
FOXA
Form 8-K
sec.gov
APGE
ABBV